Paceline and MCG Foundation advancing innovative cancer research
Since 2019, 26 community-funded innovative cancer research projects at the Georgia Cancer Center have been made possible through Paceline grants.
Researchers in the Cancer Immunology, Inflammation, and Tolerance (CIIT) research program use a range of techniques to study how the immune system influences tumorigenesis and cancer therapy. The immune system can inhibit or promote tumor progression in local tissues where pre-malignancies form. Major program themes are to elucidate
The scientific rationale for this dual approach is that pre-malignant cells create and sustain tolerance during tumor progression, while breaking tumor-associated tolerance is necessary for successful anti-tumor treatment. Hence, program goals are to elucidate molecular and cellular pathways at sites of inflammation that promote or break immune tolerance using pre-clinical mouse models of tumor progression and autoimmune syndromes, and developing novel immunotherapies to treat these syndromes more effectively by targeting tolerance pathways. To this end, program faculty also engage in promoting pre-clinical research and early-phase clinical trials of novel vaccine adjuvants to improve cancer immunotherapy, in some cases with corporate partners.
To pursue these focused research themes and scientific goals, program faculty employ many state-of-the-art techniques, facilities, and unique resources, including flow cytometric sorting and analysis, a range of molecular imaging techniques, genomic analysis, and genetically modified mouse strains. Future program development will build on existing CIIT program strengths by recruiting new investigators with expertise in inflammation, immunological, and metabolic research to complement current research focused on regulation of adaptive immunity.
Rafael Czepielewski, Ph.D.
I was trained as a physician, but has been fascinated by how our body’s immune system has been so effective to control not only microbial infections, but also cancer cells. We had studied the basic mechanism of how cancer vaccines activated immune responses and applied the vaccine design technologies into developing liver cancer vaccines. Over the last decade, research in my lab has been focusing on identifying novel T cell receptors (TCR) and on developing new chimeric antigen receptors (CAR) for liver cancer immunotherapy. We are fortunate that our research has been continuously funded by NCI/NIH grants. Our goal is to engineer immune T cells to become potent and targeted fighters to eliminate cancer cells and cure cancer patients.
Since 2019, 26 community-funded innovative cancer research projects at the Georgia Cancer Center have been made possible through Paceline grants.
“It is a great opportunity because we have a lot of great colleagues and great support in terms of core facilities and staff,” says Ahmed Chadli, PhD.
The grant awarded for Chadli’s research focuses on a specific protein, UNC45A, that can be used as a promising novel immunotherapeutic target in treating triple-negative breast cancer (TNBC).
This summer, high school students participated in the Georgia Cancer Center's first Summer Research Experience Program.